Biopharma ends decade with near-record investment — but is it going to the right places?
In 2009, the mood at JP Morgan was somber. I wasn’t there — your humble correspondent was learning algebra at the time — but that year, the financial crisis came to biotech and conversations at the often-audacious Westin centered around sheer survival. The traditional lavish opening-night gala was canceled.
Venture funding would indeed fall that year, but what followed was a decade of almost unimpeded growth. After the amount raised for healthcare venture crashed 65% to $1.8 billion in 2009, it doubled back in 2010 to $3.6 billion and, according to the annual report just released by SVB Leerink, grew until the amount raised in the last year of the decade was $10.7 billion, more than five times the first year.
“We’ve seen a really nice upcycle since 2013 in IPOs and investment,” report author Jonathan Norris told Endpoints News. “And a lot of people in 2016 thought the ride was over but now here we are in 2020, and we’ve had the best two years we’ve seen.”
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.